BNET Industries
Last Fiscal Year Sales:$11.5M
- Public
- US
Dow Jones Description
Upon Joe McCarthy's death in 1983, the firm was restructured and renamed McCarthy, Wharton, Wilson & Ethridge. In 1985, Jim Wharton relocated to Annapolis, Maryland and relinquished his partnership, and the firm became McCarthy, Wilson & Ethridge. During the following two years, more space was needed and an addition of 3,000 square feet was added to the 104 South Washington Street office. From 1985 to the present, McCarthy Wilson has expanded greatly. The firm presently consists of nine partners and eleven associates. There are fourteen secretaries, eleven paralegals, eight law clerks, a receptionist, an office manager, and a billing clerk. Because of the expansion of personnel and the need for additional office space, in March of 1997, the property located at 108 South Washington Street was added to the houses belonging to McCarthy Wilson. Being housed in 100, 104 and 108 South Washington Street, in the historic district, provides a unique and pleasant working environment, even though rumor has it that "100" is occupied by a ghost. Several of the firm's employees attest that they have seen a young woman, dressed in white, standing by the fireplace or walking the upper hall. Chuck Wilson denies the existence of a ghostly apparition but everyone notices that his office is strategically located in "104." McCarthy Wilson has remained active in the Peerless Group, an organization dedicated to preserving the historical atmosphere of the sites in Rockville. ...
Interim President and Chief Executive OfficerVaughn M. Kailian
Number of Employees 55
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
News & Analysis
Filter by
memory pharmaceuticals corp. - All News and Analysis
Memory Pharmaceuticals Corp. Q3 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions Your first question comes from Terence Flynn – Lazard Capital Markets. Terence C. Flynn – Lazard Capital Markets First on 3454, just wondering if you can share with us any additional details of the potential design of the Alzheimer’s disease trial and possibly...
Memory Pharmaceuticals Corp Q2 2008 Earnings Call Transcript
Question-and-Answer SessionOperator [Operator Instruction]. Your first question comes from the line of Terence Flynn from Lazard Capital Markets. You may proceed. Terence C. Flynn Hi, good morning and thanks for taking the questions. First, just on the proof-of-concept Phase 2a for 1414. I’m just wondering if you guys have...
Memory Pharmaceutical Q4 2007 Earnings Call Transcript
Question-and-Answer SessionOperator Thank you. Operator Instructions Your first question comes on the line of Terence C. Flynn with Lazard Capital Markets, please proceed. Terence C. Flynn - Lazard Capital Markets Hi, good morning, thank for taking the questions. Just two questions, the first I am just wondering...
Additional Resources
Hercules Technology Announces Approximately $5.5 Million in Additional Early Repayment of Debt Investments and Further De-leveraging
Total Fourth Quarter Early Principal Repayments Total Over $40.0 Million PALO ALTO, Calif. -- Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC), the leading specialty finance company providing venture debt and equity to venture capital and private equity backed technology and life science companies at all stages of development,...
Swiss pharma major Roche is acquiring US biopharmaceuticals concern Memory Pharmaceuticals for 50m [pounds sterling]
Swiss pharma major Roche is acquiring US biopharmaceuticals concern Memory Pharmaceuticals for 50m [pounds sterling]. Memory specialises in the treatment of central nervous system disorders including Alzheimer's disease and schizophrenia, and has been partnering Roche in clinical trials of drug candidates in these fields...
M&A activity continues to recast the industry
NEW YORK -- The year is ending in much the same way as it began for the pharmaceutical industry as mergers and acquisitions rule the spotlight. King Pharmaceuticals Inc., for example, announced late last month that it plans to acquire Alpharma Inc. for about $1.6 billion. Johnson &...
Roche Buys Memory To Boost Its Pipeline
NUTLEY - Swiss drug maker Roche, which has its United States headquarters in the township, last week signed a $50 million deal to buy Memory Pharmaceuticals, its Montvale-based partner in develop- ing a drug for Alzheimer's disease. Memory makes drugs for diseases of the central nervous system, such as Alzheimer's...
Has added Memory Pharmaceuticals Corp. to their watch list.
M2 PRESSWIRE-12 March 2008-The Maybach Review: Has added Memory Pharmaceuticals Corp. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:12032008 Maybach Financial is a syndicate of financial informants representing a true investing experience. Taking research from financial consultants, brokers,...
Memory Pharmaceuticals Corp. Changes and Reallocates Programs.
M2 PRESSWIRE-12 March 2008-NASDAQNEWS: Memory Pharmaceuticals Corp. Changes and Reallocates ProgramsC1994-2008 M2 COMMUNICATIONS LTD RDATE:13032008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate. Do you have...
Memory Pharmaceuticals Corp. Reports the Fourth Quarter and Year end Results.
M2 PRESSWIRE-7 March 2008-NASDAQNEWS: Memory Pharmaceuticals Corp. Reports the Fourth Quarter and Year end ResultsC1994-2008 M2 COMMUNICATIONS LTD RDATE:07032008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Vaughn M. Kailian | Interim President and Chief Executive Officer |
| David A. Lowe | Chief Scientific Officer |
| James R. Sulat | Chief Financial Officer |
| Stephen R. Murray | CMO |
| Hans-Jnrgen Hess | Vice President, Research |
| Joseph M. Donabauer | Controller & Vice President |
| Jzaneen Lalani | Vice President, Legal Affairs |
| Michael Murray | Vice President, Preclinical Drug Development |
| Michael P. Smith | Vice President of Business Development |
| Jonathan Fleming | Co-Founder |
| Robert I. Kriebel | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Alix Marduel | Board of Directors |
| Anthony B. Evnin | Board of Directors |
| Larry R Squire | Board of Directors |
| Mark Leschly | Board Member |
| Michael Meyers | Board of Directors |
| Paul Blake | Board of Directors |
| Peter F. Young | Board of Directors |
| Richard Mayeux | Board of Directors |
| Scott Small | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Memory Pharmaceuticals Corp. | Interim President and Chief Executive Officer | Current |
| MPM Capital Limited Partnership | General Partner | Current |
| Feinstein Kean Healthcare | Current | |
| Cerimon Pharmaceuticals, Inc. | Chairman | Current |
| ViaCell, Inc. | Chairman | Current |
| California Healthcare Institute, Inc. | Chairman | Current |
| Elixir Pharmaceuticals, Inc. | Chairman | Current |
| Amylin Pharmaceuticals, Inc. | Director | Current |
| Nehi | Board of Directors | Current |
| Bioventures, Inc. | Director | Current |
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| Cephalon, Inc. | Board of Directors | Current |
| Windhover Information, Inc. | Director | Current |
| Eisenhower Fellowships | Board of Directors | Current |
| Nicox S.A. | Director | Current |
| Personalized Medicine Coalition | Board of Directors | Current |
| The University of Texas at Austin | Member | Current |
| Bioventures, Inc. | Member | Current |
| COR Therapeutics, Inc. | CEO | Former |
| COR Therapeutics, Inc. | President | Former |
| Marion Merrell Dow | NA | Former |
| Rigid Building Systems Ltd. | Co-Chairman | Former |
| Ikaria, Inc. | Chairman of The Ikaria Board of Directors | Former |
| Millennium Pharmaceuticals, Inc. | Vice Chairman | Former |
| COR Therapeutics, Inc. | Director | Former |
| Biotechnology Industry Organization | Director | Former |
| Tufts University | B.A. | Former |
| Organization | Position | Status |
|---|---|---|
| Memory Pharmaceuticals Corp. | Chief Scientific Officer | Current |
| Alta Partners | Chief Scientific Officer and Director | Current |
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| Envivo Pharmaceuticals, Inc. | Chief Executive Officer | Former |
| Envivo Pharmaceuticals, Inc. | President | Former |
| Roche Bioscience | Vice President | Former |
| Roche Bioscience | Therapeutic Area Head | Former |
| Envivo Pharmaceuticals, Inc. | CNS | Former |
| University of Leeds | Ph.D. In Neurobiology | Former |
| University of Bristol | B.Sc. | Former |
| Organization | Position | Status |
|---|---|---|
| Alta Partners | President, Chief Executive Officer and Director | Current |
| Memory Pharmaceuticals Corp. | Chief Financial Officer | Current |
| Intercell Ag | Developer | Current |
| Maxygen, Inc. | Chairman | Current |
| Maxygen, Inc. | Director | Current |
| Intercell Ag | Director | Current |
| Momenta Pharmaceuticals, Inc. | Board of Directors | Current |
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| Memory Pharmaceuticals Corp. | Chief Executive Officer | Former |
| R.R. Donnelley & Sons Co. | Chief Financial Officer | Former |
| Chiron | Chief Financial Officer | Former |
| R.R. Donnelley & Sons Co. | Senior Executive Vice President | Former |
| Moore Wallace | Senior Executive Vice President | Former |
| Chiron | Vice President | Former |
| Stanford University | M.B.A. | Former |
| Yale University | B.S. | Former |
| Organization | Position | Status |
|---|---|---|
| Memory Pharmaceuticals Corp. | CMO | Current |
| Memory Pharmaceuticals Corp. | Vice President, Clinical Dev | Former |
| University of California, San Francisco | Residency Department of Psychiatry | Former |
| American Board of Psychiatry and Neurology, Inc. | Former | |
| Pfizer Inc. | Former | |
| Medical University of South Carolina | M.D. and Ph.D. In Molecular Biology | Former |
| University of South Carolina | Bachelor of Science | Former |
| Organization | Position | Status |
|---|---|---|
| Memory Pharmaceuticals Corp. | Vice President, Research | Current |
| Organization | Position | Status |
|---|---|---|
| Memory Pharmaceuticals Corp. | Controller & Vice President | Current |
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| Memory Pharmaceuticals Corp. | Principal | Former |
| SPX Corporation | Former | |
| Reckitt Benckiser, Inc. | Former | |
| Genzyme Corporation | Former | |
| Genzyme Biosurgery | Former | |
| General Signal Corporation | Former |
Jzaneen Lalani has served as our Vice President, Legal Affairs since June 2004. From February 2003 to May 2004, Ms. Lalani was a member of the Corporate and Commercial Law Group at Kronish Lieb Weiner & Hellman LLP, where she worked with privately held and publicly traded companies on transactions including mergers and acquisitions, financings and securities offerings. From October 1999 to February 2003, Ms. Lalani was a member of the Business & Technology Group at Brobeck Phleger & Harrison LLP, where her practice also included representing emerging growth companies and newly-public companies. Ms. Lalani received a B.Sc. in 1993 from Queen s University in Ontario, her LL.B. in 1996 from the University of Victoria, in British Columbia, and a Master of International Affairs and a Masters of Law from Columbia University in 1999. Ms. Lalani is admitted to the British Columbia Bar and the New York Bar and is licensed as an in-house counsel in the State of New Jersey.
| Organization | Position | Status |
|---|---|---|
| Memory Pharmaceuticals Corp. | Vice President, Legal Affairs | Current |
| New Jersey & Company | Counsel | Current |
| Kronish Lieb Weiner & Hellman Llp | Member | Former |
| Memory Pharmaceuticals Corp. | General Counsel | Former |
| Columbia University | Masters of Law | Former |
| Columbia University | B.Sc. | Former |
| Organization | Position | Status |
|---|---|---|
| Memory Pharmaceuticals Corp. | Vice President, Preclinical Drug Development | Current |
Michael P. Smith, Vice President of Business Development. From 2004 to 2006, Mr. Smith served as Vice President of Business Development for QLT, Inc., a global biopharmaceutical company, where he was responsible for all business development activities as well as corporate strategy. From 1998 to 2004, Mr. Smith was with Chiron Corporation, a biotechnology company, where he held several senior positions, including Manager, Corporate Finance and Business Development and Director Corporate Development, and was responsible for developing and implementing M&A and strategic partnership transactions and strategies. Prior to joining Chiron Corporation, Mr. Smith was the Finance/Business Development Manager for Ascent Logic Corporation, a private systems engineering software company. Mr. Smith holds a B.S. from the University of Virginia, as well as an MBA from the University of California, Berkeley.
| Organization | Position | Status |
|---|---|---|
| Memory Pharmaceuticals Corp. | Vice President of Business Development | Current |
| Morrison & Foerster LLP | summer associate | Current |
| Legalpeople LLC | Current | |
| QLT, Inc. | Vice President of Business Development | Former |
| Ascent Logic | Business Development Manager | Former |
| The Dow Chemical Company | Senior Research Scientist | Former |
| American Intellectual Property Law Association | member | Former |
| Berkeley Technology Law Journal | article editor | Former |
| Chiron | Former | |
| United States Patent and Trademark Office | Former | |
| California Institute of Technology | Ph.D. in Organic Chemistry | Former |
| University of California, Berkeley | J.D. | Former |
| University of California, Berkeley | MBA | Former |
| University of California, Berkeley | A.B. in anthropology | Former |
| University of Virginia | B.S. | Former |
Jonathan J. Fleming is one of our co-founders and is Chairman of our Board of Directors. Mr. Fleming served as Chairman from January 1998 to May 2005 and assumed the position again in October 2006. Mr. Fleming has served as the Managing Partner of Oxford Bioscience Partners, a venture capital firm specializing in life science technology since 1996. Prior to joining Oxford Bioscience, he served as a Founding Partner of MVP Ventures in Boston, Massachusetts. Mr. Fleming serves as a member of the board of directors of Imcor Pharmaceutical Co. (formerly Photogen Technologies, Inc.), a specialty pharmaceutical company focused on developing medical imaging pharmaceutical products. He also serves as Chairman of the board of directors of BioProcessors Corporation, a privately-held corporation, and as a director of seven other privately-held companies, including Leerink Swann & Company, Inc., a Boston-based investment bank specializing in health care companies. Mr. Fleming is a Trustee of the Museum of Science in Boston and is a Senior Lecturer at Massachusetts Institute of Technology's Sloan School of Management. Mr. Fleming received a B.A. from the University of California, Berkeley and a Masters in Public Administration from Princeton University.
| Organization | Position | Status |
|---|---|---|
| Memory Pharmaceuticals Corp. | Co-Founder | Current |
| Oxford Bioscience Partners | Managing Partner | Current |
| Massachusetts Life Sciences Collaborative | Managing General Partner, Oxford Bioscience Partners | Current |
| MIT Sloan School of Management | Senior Lecturer | Current |
| Massachusetts Institute of Technology | Senior Lecturer | Current |
| The Convergence Forum | Current | |
| Centagenetix, Inc. | Current | |
| Hypnion, Inc. | Current | |
| BioProcessors Corp. | Chairman | Current |
| Asterand, Plc. | Board of Directors | Current |
| Synaptic Pharmaceutical Corp | Director | Current |
| Imcor Pharmaceutical Co | Board of Directors | Current |
| Nehi | Board of Directors | Current |
| Museum of Science | Board of Directors | Current |
| Elixir Pharmaceuticals, Inc. | Board of Directors | Current |
| Alta Partners | Director | Current |
| Railrunner | Board of Directors | Current |
| Leerink Swann & Company | Board of Directors | Current |
| Braincells, Inc. | Board of Directors | Current |
| Museum of Science | Trustee | Current |
| Medica Venture Partners | Co-Founder | Former |
| Tvm Techno Venture Management | General Partner | Former |
| MVP Ventures | Founding General Partner | Former |
| Medica Venture Partners | Special Limited Partner | Former |
| Oxford Bioscience Partners | Owner | Former |
| Biotechnology Venture Investors Group | Chairman | Former |
| Princeton University | Master's Degree In Public Administration | Former |
| University of California | B.A. | Former |
| University of California, Berkeley | Bachelor of Arts Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Alta Partners | Managing Director | Current |
| Syntonix Pharmaceuticals, Inc. | Director | Current |
| Genteric Inc. | Board of Directors | Current |
| Corcept Therapeutics Incorporated | Member of the Board of Directors | Current |
| Alta Partners | Director | Current |
| NeurogesX, Inc. | Board of Directors | Current |
| Metabolex, Inc. | Board of Directors | Current |
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| Sofinnova Ventures, Inc. | General Partner | Former |
| Sofinnova Ventures, Inc. | venture career | Former |
| CV Therapeutics Inc. | Key Investor | Former |
| Aviron | Key Investor | Former |
| Rigid Building Systems Ltd. | Key Investor | Former |
| The Medicines Company | Key Investor | Former |
| University of Paris | Doctorate | Former |
| Stanford University | postdoctoral fellowship | Former |
| University of California | postdoctoral fellowship | Former |
| University of California, San Francisco | Former | |
| The University of California, San Francisco | Former |
Anthony B. Evnin, Ph.D. , a director since October 2006, is a General Partner of Venrock, a venture capital firm, where he has been a Partner since 1975. He is currently a member of the Board of Directors of Icagen, Inc., Infinity Pharmaceuticals, Inc and Sunesis Pharmaceuticals, Inc., as well as being on the Board of Directors of a number of private companies. Dr. Evnin received an A.B. in Chemistry from Princeton University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.
| Organization | Position | Status |
|---|---|---|
| Venrock Associates | Managing General Partner | Current |
| Pharmos Corporation | Managing General Partner, Venrock Associates | Current |
| Renovis, Inc. | Board of Directors | Current |
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
| Vela Pharmaceuticals, Inc. | Current | |
| Infinity Pharmaceuticals, Inc | Chair of Infinity's Nominating and Governance Committee | Current |
| Venrock Associates | Board of Directors | Current |
| Acceleron Pharma Inc | Board of Directors | Current |
| The Rockefeller University | Board of Directors | Current |
| Uv Partners | Board of Directors | Current |
| Coley Pharmaceutical Group Inc. | Board of Directors | Current |
| Icagen, Inc. | Board of Directors | Current |
| Alta Partners | Director | Current |
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| Pharmos Corporation | Director | Current |
| Altea Therapeutics | Board Member | Current |
| Metabolex, Inc. | Board Member | Current |
| Aveo Pharmaceuticals, Inc. | Board of Directors | Current |
| Cancer Immunity | Board of Directors | Current |
| Triangle Pharmaceuticals, Inc. | Board of Directors | Current |
| Celladon | Director | Current |
| Caliper Technologies | Board of Directors | Current |
| Syntonix Pharmaceuticals, Inc. | Director | Current |
| Sonic Innovations, Inc. | Board of Directors | Current |
| Union Carbide Corporation | Research Scientist | Former |
| Gilead Sciences, Inc. | Former | |
| Sunesis Pharmaceuticals, Inc. | Board of Directors | Former |
| IDEXX Laboratories, Inc. | Investor | Former |
| Sepracor Inc. | Investor | Former |
| Triangle Pharmaceuticals, Inc. | Investor | Former |
| Sonic Innovations, Inc. | Investor | Former |
| Centocor, Inc. | Investor | Former |
| Caliper Life Sciences, Inc. | Investor | Former |
| IDEC Pharmaceuticals | Investor | Former |
| Massachusetts Institute of Technology | Ph.D. in chemistry | Former |
| Massachusetts, Inc. | Ph.D. In Chemistry | Former |
| Princeton University | A.B. | Former |
| Memory Pharmaceuticals Corp. | member | Former |
Larry R. Squire, Ph.D., University Professor, VA Medical Center in La Jolla, California, and a Professor at the University of California San Diego. Dr. Squire is a leading scientist in the field of human and non-human primate memory. A former President of the Society of Neuroscience, he has helped define the basic distinction between the declarative and non-declarative memory systems of the brain. Dr. Squire sits on the editorial board of Learning & Memory Journal and on the board of directors of the McKnight Endowment Fund for Neuroscience. He was elected Member of the National Academy of Science in 1993. He is the co-author of Memory, From Mind to Molecules.
| Organization | Position | Status |
|---|---|---|
| Kansas City VA Medical Center | Professor | Current |
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| University of California, San Diego | Professor | Former |
| Organization | Position | Status |
|---|---|---|
| Rho Ventures | Managing Partner | Current |
| Terahealth, Inc. | Managing Partner of Rho Ventures and Serves | Current |
| Medical Present Value Inc. | Managing Partner, Rho Ventures | Current |
| Senomyx, Inc. | Chairman | Current |
| Medical Present Value Inc. | Board of Directors | Current |
| Rho Fund Investors | Board Member | Current |
| OraMetrix, Inc. | Board Member | Current |
| Memory Pharmaceuticals Corp. | Board Member | Current |
| Verenium Corporation - Specialty Enzymes | Director | Current |
| Sitv, Inc. | Board Member | Current |
| NitroMed, Inc. | Director | Current |
| Terahealth, Inc. | Board of Directors | Current |
| Diversa Corporation | Director | Current |
| NitroMed, Inc. | Committee Member | Current |
| Senomyx, Inc. | Member | Current |
| Healthcare Ventures, LLC | general partner | Former |
| Health Care Ventures LLC | General Partner | Former |
| Rho Capital Partners, Inc. | Managing Partner | Former |
| Anacor Pharmaceuticals, Inc. | Managing Partner of Rho Ventures and Chairman of Anacor's Board of Directors | Former |
| Tercica, Inc. | Director | Current |
| Senomyx, Inc. | Director | Former |
| Stanford Graduate School of Business | M.B.A. | Former |
| Harvard University | A.B. | Former |
| Organization | Position | Status |
|---|---|---|
| Dominick & Dominick, LLC | Current | |
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| Merrill Lynch & Co., Inc. | Director, Biotechnology and Pharmaceutical Investment Banking | Former |
| The Bear Stearns Companies Inc. | Former | |
| Lehman Brothers Holdings Inc. | Former | |
| D-and_D.Com | Former | |
| Manhattan College | BS in Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Intranasal Technology, Inc | President and Chief Executive Officer | Current |
| Alphavax, Inc | CEO | Current |
| Alphavax, Inc | President | Current |
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| Alta Partners | Director | Current |
| Intranasal Technology, Inc | Board of Directors | Current |
| Positions, Inc. | Former | |
| Abbott International LLC | Former | |
| Indiana University | MBA In Marketing | Former |
| Indiana University | BA In History | Former |
Richard Mayeux is the Gertrude H. Sergievsky Professor of Neurology, Psychiatry and Epidemiology at Columbia University. He is the director of the Gertrude H. Sergievsky Center and the co-director of the Taub Institute for Research on Alzheimer's Disease and the Aging Brain. Born in New Orleans, Louisiana, he is a graduate of Oklahoma State University and the University of Oklahoma Health Sciences, School of Medicine. He also holds a masters degree in Epidemiology from Columbia University. He completed residencies in both Internal Medicine (Boston City Hospital, Boston University) and Neurology (Columbia Presbyterian Medical Center, Columbia College of Physicians and Surgeons). He also completed post-doctoral training fellowship in Behavioral Neurology at the Boston Veterans Administration Medical Center (at Boston University) with D. Frank Benson, funded by the National Institute of Health.
| Organization | Position | Status |
|---|---|---|
| Sergievsky Center and Co | Director Emeritus | Current |
| Sergievsky Center and Co | Professor of Neurology, Psychiatry, and Epidemiology | Current |
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| Sergievsky Center and Co | Director | Current |
| Columbia University | Co-Director | Former |
| Boston City Hospital | Residencies | Former |
| Oklahoma State University | M.D. in | Former |
| Columbia University | Masters Degree In Epidemiology | Former |
| Oklahoma State University | B.S. In 1968, Both | Former |
| Organization | Position | Status |
|---|---|---|
| Alta Partners | Director | Current |
| Elixir Pharmaceuticals, Inc. | Board of Directors | Current |
| Memory Pharmaceuticals Corp. | Director | Current |
| US Bioscience | Executive Vice President, Chief Financial Officer and Director | Former |
| Neose Technologies, Inc. | Chief Financial Officer | Former |
| Neose Technologies, Inc. | Senior Vice President | Former |
| Rhone-Poulenc Rorer | Former | |
| US Bioscience | Director | Former |
| Roanoke College | B.S. In Economics | Former |
Scott Small, M.D., Herbert Irving Assistant Professor in Neurology at Columbia University and Taub Scholar at the Taub Institute. With a background in cellular physiology, Dr. Small has focused on using new imaging modalities to investigate both normal and pathological mechanisms of the brain. Dr. Small was the first investigator at Columbia University to use functional magnetic resonace imaging (fMRI), and he led a team of investigators who published the first paper showing the utility of fMRI for detecting Alzheimer's disease and for characterizing memory decline in the aging population. More recently, he has developed a novel high-resolution application of fMRI, which can be used to investigate physiologic dysfunction in the mouse brain.
| Organization | Position | Status |
|---|---|---|
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| Columbia University | Investigator | Former |
| Columbia University | M.D. | Former |
Executive News
-
Xanodyne Announces Appointment of Mr. Vaughn M. Kailian of MPM Capital to the Board of Directors
-
Xanodyne names new board member
-
XenoPort to Present at the Piper Jaffray Fourth Annual Europe Conference
-
Schaeffer's Option Blog: Call Traders Jump on Savient Pharmaceuticals' FDA News
-
Abraxis Bioscience Launches ABRAXANE in China for Women with Metastatic Breast Cancer
-
Reportlinker Adds R&D Cost Cutting: Managing Cost Containment and Safeguarding Productivity
-
GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting
-
Jubilant to Work With Endo Pharmaceuticals on Drug Development
-
iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board
-
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
-
Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
-
Pfizer s Oral JAK-3 Inhibitor Demonstrates Statistically Significant Response For Patients with Rheumatoid Arthritis, New Phase 2 Studies Show
-
Xanodyne Announces Appointment of Mr. Vaughn M. Kailian of MPM Capital to the Board of Directors
-
Xanodyne Announces Appointment of Mr. Vaughn M. Kailian of MPM Capital to the Board...
-
Vaughn Kailian joins Xanodyne board of directors
-
Xanodyne Announces Appointment of Mr. Vaughn M. Kailian of MPM Capital to the Board of Directors
-
Vaughn Kailian joins Xanodyne board of directors
-
Valeritas names new CEO
-
Valeritas Announces Appointment of New CEO
Industry Transcripts by Seeking Alpha
-
BMP Sunstone Corporation Q1 2009 Earnings Call Transcript
on Jun 30, 2009about BJGP
-
Matrixx Initiatives, Inc., F4Q09 (Qtr End 03/31/09) Earnings Call Transcript
on May 12, 2009about MTXX
-
King Pharmaceuticals Inc., Q1 2009 Earnings Call Transcript
on May 11, 2009about KG
-
Flamel Technologies SA Q1 2009 Earnings Call Transcript
on May 11, 2009about FLML
-
Sucampo Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
on May 08, 2009about SCMP
Glass Door
IndustryTop Rated
- AstraZeneca's Seroquel Research Director Confessed to Sex-for-Studies Affairs 17 votes
- Forest Labs' Lexapro Flap Over JAMA Article Will Likely Be Examined by the Feds 11 votes
- Medarex Execs Got 10% Pay Raise Despite Delivering Nothing 11 votes
- Pfizer District Sales Manager Guilty of Altering Off-Label Celebrex Documents 10 votes
- Gilead Whistleblower Suit: A Bullet Dodged 10 votes
